Advanced Search: Hematologic

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201901148

A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease

201902007

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

201905082

A Phase Ib Study of AZD6738 for Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy

201911131

A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

201911163

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

202002074

AN EXPLORATORY PHASE 1B OPEN-LABEL MULTIARM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CC-90009 IN COMBINATION WITH ANTI-LEUKEMIA AGENTS IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA

202003066

Evaluation of Vigamox Treatment for Ocular Graft-Versus-Host Disease

202006109

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis

202007143

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis

202008120

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia